Recent Updates
Recently added Catalysts
DMAC

DiaMedica Issues Stock Option Grant

Key Takeaway: MINNEAPOLIS, Aug. 23, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA) (OTCQB:DMCAF), today announces it has issued 600,000 stock options to new employees and advisors of the Company.  The options were issued at $0.52 per share and have a ten

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~16 mo
Low dilution risk
Lead asset
Recombinant human tissue kallikrein
Phase 2 · Acute Ischemic Stroke

Full Press Release Details

MINNEAPOLIS, Aug. 23, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA) (OTCQB:DMCAF), today announces it has issued 600,000 stock options to new employees and advisors of the Company.  The options were issued at $0.52 per share and have a ten-year term.
The options were granted under the Company's Stock Option Plan and are part of the Company's long term incentive/retention plan for employees and directors. The option issuance is subject to the approval of the TSX Venture Exchange.
About DiaMedica Therapeutics Inc.
Vice President of Business Development
DiaMedica Therapeutics Inc.
Phone: (617) 899-5941
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.
Last updated: Aug 23, 2018